| Identification | Back Directory | [Name]
Losmapimod (GW856553X) | [CAS]
585543-15-3 | [Synonyms]
CS-1186
GSK-AHAB
SB856553
GW-856553
GW 856553X
LosMapiMod
SB0856553)
LosMapiMod,GW-856553
MIS-21394 LOSMAPIMOD
Losmapimod (GW856553X)
Losmapimod (GW0856553X
Losmapimod (GW856553X) USP/EP/BP
6-[5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-
6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide. Losmapimod,GW-856553 | [Molecular Formula]
C22H26FN3O2 | [MDL Number]
MFCD16619322 | [MOL File]
585543-15-3.mol | [Molecular Weight]
383.46 |
| Chemical Properties | Back Directory | [Boiling point ]
529.4±50.0 °C(Predicted) | [density ]
1.20±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥19.15 mg/mL in DMSO | [form ]
solid | [pka]
7.75±0.46(Predicted) |
| Hazard Information | Back Directory | [Description]
GW 856553X is a dual inhibitor of p38α and p38β MAPK (Kis = 0.0079 and 0.025 μM, respectively, in cell-free assays).1 It is selective for p38α and p38β MAPK over p38γ and p38δ MAPK when used at a concentration of 10 μM. GW 856553X inhibits LPS-induced TNF-α production in isolated rat and human peripheral blood mononuclear cells (PBMCs; IC50s = 0.6 and 0.13 μM, respectively). It decreases disease severity in a mouse model of collagen-induced arthritis when administered at doses ranging from 0.8 to 20 mg/kg.2 GW 856553X (1.2 and 12 mg/kg) improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet.1 | [Uses]
Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor. | [Definition]
ChEBI: 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide is a phenylpyridine. | [target]
p38α | [storage]
Store at -20°C | [References]
[1]. willette rn, eybye me, olzinski ar, et al. differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. j pharmacol exp ther, 2009, 330(3): 964-970.
[2]. cheriyan j, webb aj, sarov-blat l, et al. inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. circulation., 2011, 123(5): 515-523.
[3]. lomas da, lipson da, miller be, et al. an oral inhibitor of p38 map kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. j clin pharmacol, 2012, 52(3): 416-424. |
|
|